Pfizer's leukemia drug Bosulif wins conditional EU approval

03/29/2013 | Pharmaceutical Business Review Online

Pfizer obtained conditional approval from the European Commission to market Bosulif, or bosutinib, for adults with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitors, who can't take imatinib, nilotinib and dasatinib. The approval was based on positive data from a Phase I/II trial involving more than 500 Ph+CML patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY